olaparib Clinical Research Trials

Please select a valid location from the dropdown

Found 124 clinical trials

featured

A Phase III, Randomised, Double Blind, Placebo Controlled, Multicentre Study of Maintenance Olaparib Monotherapy in Patients With gBRCA Mutated Metastatic Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum Based Chemotherapy

A Phase III, Randomised, Double Blind, Placebo Controlled, Multicentre Study of Maintenance Olaparib Monotherapy in Patients With gBRCA Mutated Metastatic Pancreatic Cancer Whose Disease Has Not

326 views
08 Nov, 2020
27 locations

Efficacy and Safety of Olaparib Olaparib + Bevacizumab Compared to Bevacizumab + 5-Fluorouracil (FU)

This is an efficacy and safety study of olaparib alone or in combination with bevacizumab being compared to bevacizumab with Fluorouracil (5-FU) in participants with unresectable or metastatic

systemic chemotherapy

adenocarcinoma

colorectal adenocarcinoma

solid tumour

fluorouracil

10 views
04 Mar, 2021
98 locations

Investigating Safety Tolerability Efficacy and PK of Olaparib in Paediatric Patients With Solid Tumours

A study to find out whether olaparib is safe and well tolerated when administered to children and adolescents with solid tumours.

16 views
03 Mar, 2021
20 locations

Efficacy of Olaparib in Advanced Cancers Occurring in Patients With Germline Mutations or Somatic Tumor Mutations in Homologous Recombination Genes

At present targeted therapy with the PARP inhibitor olaparib has become standard of care in advanced platinum sensitive BRCA1/2 mutant ovarian cancer. The key in this sensitivity is the loss of

0 views
25 Jan, 2021
1 location

Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab Followed by Maintenance Durvalumab Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer Patients.

bevacizumab followed by maintenance durvalumab and bevacizumab or durvalumab, bevacizumab and olaparib in patients with newly diagnosed advanced ovarian cancer.

84 views
17 Feb, 2021
282 locations

Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK-7339-002 / LYNK-002)

This study will evaluate the efficacy and safety of olaparib (MK-7339) monotherapy in participants with multiple types of advanced cancer (unresectable and/or metastatic) that: 1) have

135 views
04 Mar, 2021
144 locations

Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365)

be nine cohorts in this study: Cohort A will receive pembrolizumab + olaparib, Cohort B will receive pembrolizumab + docetaxel + prednisone, Cohort C will receive pembrolizumab + enzalutamide, Cohort

gonadotropin releasing hormone

serum testosterone

abiraterone

adenocarcinoma

luteinizing hormone

0 views
18 Feb, 2021
11 locations

Olaparib for PAH: a Multicenter Clinical Trial

can reverse PAH in several animal models1. Interestingly, PARP1 inhibition is also cardioprotective. Olaparib, an orally available PARP1 inhibitor, can reverse cancer growth in animals and humans with

pulmonary disease

hysterectomy

cancer

body mass index

serum pregnancy test

4 views
24 Jan, 2021
4 locations

Radiotherapy & Olaparib in COmbination for Carcinoma of the Oesophagus

The purpose of this study is to determine the Maximum Tolerated Dose (MTD) of olaparib in combination with radical radiotherapy in patients with oesophageal cancer who are unsuitable for

adenocarcinoma

chemoradiotherapy

neutrophil count

cancer

oesophageal stent

2 views
08 Nov, 2020

Paclitaxel Pembrolizumab and Olaparib in Previously Treated Advanced Gastric Adenocarcinoma

The purpose of this study is to evaluate the safety and clinical activity of paclitaxel plus olaparib and pembrolizumab in patients with previously treated advanced Gastric Cancer (GC).

0 views
25 Jan, 2021
1 location

Filter By

Found 124 clinical trials